|Articles|July 31, 2017

LabCorp to Acquire Chiltern for Approximately $1.2 Billion

LabCorp-global life sciences company-and specialty CRO, Chiltern, announced that LabCorp will acquire Chiltern in an all-cash transaction for approximately $1.2 billion. Following the completion of the transaction, Chiltern will become part of LabCorp’s Covance segment.

Read the full release here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related Content

Lab orchestration is often reduced to scheduling and automation, but a connected scientific record across the physical, logical, and digital domains is what actually makes AI-ready research possible. Credit: Stock.Adobe.com/VStudio.

Lab Orchestration Is Not What You Think It Is

ByRyan Bernhardt

September 11th 2026

Why Seizure Counts Alone Can't Define Success in Epilepsy Trials

ByAmélie Lothe,Andy Studna, Senior Editor

September 11th 2026

ACT Brief: Patient Voice in Protocol Design, AI-Informed Recruitment Workflows, and Engagement Maturity Beyond Performative

ByAndy Studna, Senior Editor

September 11th 2026

Recruitment in the Age of AI: Q&A with John Worden, Javara

ByJohn Worden,Andy Studna, Senior Editor

September 10th 2026

What It Actually Means to Embed the Patient Voice in Trial Design

ByAmélie Lothe,Andy Studna, Senior Editor

September 10th 2026

Trending on Applied Clinical Trials Online

What It Actually Means to Embed the Patient Voice in Trial Design

Recruitment in the Age of AI: Q&A with John Worden, Javara

Beyond Compliance: NetraMark's Joseph Geraci, PhD, on Making AI-Driven Patient Subgroups Explainable

What This Study Means for Sponsors Still Struggling to Justify RBQM at Scale

From Participation to Understanding: Reframing Engagement in Clinical Trials